BINV — BioInvent International AB Share News
0.000.00%
Last trade - 00:00- SEK1.33bn
- SEK1.01bn
- SEK226.50m
Sweden's BioInvent Q2 net sales drop, loss widens
Brief: BioInvent Q2 Sales SEK 12.8 Million
Brief: BioInvent Publishes Preclinical Manuscript On BI-1808, BI-1910
Brief: BioInvent Gets FDA Fast Track Designation For BI-1808
Brief: BioInvent: New Data From BI-1206 Triplet Combination In Lymphoma
Brief: BioInvent: BI-1808 Shows Favorable Safety Profile
Sweden's BioInvent Q1 net sales fall, loss widens
Brief: BioInvent Q1 Sales SEK 13.4 Million
Brief: Bioinvent Achieves Phase 3 Milestone, Eligible For EUR 1 Mln Payment
Sweden's BioInvent posts lower net sales in Q4, focuses on accelerating advanced assets
Brief: BioInvent Q4 Sales SEK 3 Million
Brief: BioInvent Presents Promising Early Data in CTCL
Brief: BioInvent Q3 Sales SEK 3.3 Million
Brief: Transgene, Bioinvent To Present Translational Data And Updated Clinical Results On Armed Oncolytic Virus Bt-001
Europe Research Roundup: Bioinvent, Diasorin, Sandoz
Brief: Bioinvent Q2 Net Revenue SEK 198.1 Million
Brief: Bioinvent Announces Strategic Changes In Portfolio
Brief: BioInvent Q2 Sales SEK 198.1 Million
Brief: Xoma Royalty Buys Mezagitamab Royalty, Milestone Rights Held By Bioinvent For Up To $30 Mln